Mānuka Honey and Wound Care: What the Research Shows

Mānuka honey is one of the most-studied wound-care substrates in modern medicine. The evidence base spans Cochrane reviews, randomized controlled trials, and FDA medical-device clearance for sterile honey-based dressings. This article reviews what the published research has established and what it has not.

What the research has established

Mānuka honey's antibacterial activity in wound applications is well-documented. The defining mechanism, identified by Mavric et al. (2008), is its high concentration of methylglyoxal (MGO), which is heat-stable and survives the conditions that destroy regular honey's antibacterial action. This stable activity is what differentiates Mānuka from peroxide-dependent honeys for wound use.

A 2015 Cochrane review (Jull et al.) examined 26 randomized trials of honey for wound treatment and found that honey-based dressings appeared to heal acute wounds (such as burns and minor lacerations) faster than some conventional dressings, while the evidence for chronic wounds (venous leg ulcers, diabetic foot ulcers) was less conclusive. The review noted that high-quality trials were limited.

The U.S. Food and Drug Administration cleared Mānuka-honey-based wound dressings under 510(k) clearance K112112 (2011), marketed as Medihoney by Comvita. These are sterile, gamma-irradiated medical devices, not retail food honey.

What the research has not established

The evidence does not support using a jar of retail Mānuka honey on a serious wound. Retail jars are food-grade, not sterile. They can contain bacterial spores, including those of Clostridium botulinum, which is why honey is not given to infants under 12 months and why open wounds in immunocompromised patients require medical-grade dressings.

Research has also not established a "best UMF" or "best MGO" level for general wound care. Most clinical trials used either pre-sterilized medical products or specific UMF 16+ to 20+ ranges, and outcomes varied by wound type.

What this means for buyers

If you are looking at Mānuka honey because of its wound-care reputation, two things matter:

• For any open or non-trivial wound, your clinician's choice of dressing belongs to them, not to a retail jar. Sterile Mānuka honey medical products exist and are FDA-cleared for that use.
• For a retail jar to even hypothetically carry the antibacterial properties studied in the literature, it should be UMFHA-certified or carry an MGO grade. UMF 10+ corresponds approximately to MGO 263; UMF 20+ to MGO 829. See our UMF explainer and our MGO explainer for the full grading background.

The brands we have tested at the higher potency tiers are listed on our best Mānuka honey roundup.

Common questions

Is the Mānuka honey in my pantry the same as Medihoney?

No. Medihoney is a sterile medical device. The retail jar is food-grade and not sterilized.

Does higher MGO mean a wound heals faster?

The published trials do not show a clean dose-response relationship between MGO content and wound-healing rate. Higher MGO is associated with stronger antibacterial activity in laboratory tests; clinical outcomes depend on wound type, sterility of application, and other factors.

Sources

• Mavric E, Wittmann S, Barth G, Henle T. Identification and quantification of methylglyoxal as the dominant antibacterial constituent of Leptospermum scoparium (Mānuka) honeys from New Zealand. Molecular Nutrition & Food Research. 2008;52(4):483-9.
• Jull AB, Cullum N, Dumville JC, Westby MJ, Deshpande S, Walker N. Honey as a topical treatment for wounds. Cochrane Database of Systematic Reviews. 2015;(3):CD005083.
• Molan PC. The evidence and the rationale for the use of honey as wound dressing. Wound Practice and Research. 2011;19(4):204-220.
• Carter DA, Blair SE, Cokcetin NN, et al. Therapeutic Mānuka Honey: No Longer So Alternative. Frontiers in Microbiology. 2016;7:569.
• U.S. Food and Drug Administration. 510(k) Premarket Notification K112112. Medihoney Hydrocolloid (HCS) Wound Paste. 2011.